These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 32522440)

  • 1. Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma.
    Fiala MA; Wildes TM; Vij R
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):647-651. PubMed ID: 32522440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis.
    Ailawadhi S; Frank RD; Advani P; Swaika A; Temkit M; Menghani R; Sharma M; Meghji Z; Paulus S; Khera N; Hashmi SK; Paulus A; Kakar TS; Hodge DO; Colibaseanu DT; Vizzini MR; Roy V; Colon-Otero G; Chanan-Khan AA
    Cancer Med; 2017 Dec; 6(12):2876-2885. PubMed ID: 29105343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
    Ailawadhi S; Frank RD; Sharma M; Menghani R; Temkit M; Paulus S; Khera N; Hashmi S; Advani P; Swaika A; Paulus A; Aslam N; Sher T; Roy V; Colon-Otero G; Chanan-Khan A
    Cancer; 2018 Apr; 124(8):1710-1721. PubMed ID: 29360160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Racial disparities in treatment use for multiple myeloma.
    Fiala MA; Wildes TM
    Cancer; 2017 May; 123(9):1590-1596. PubMed ID: 28085188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis.
    Ailawadhi S; Parikh K; Abouzaid S; Zhou Z; Tang W; Clancy Z; Cheung C; Zhou ZY; Xie J
    Blood Adv; 2019 Oct; 3(20):2986-2994. PubMed ID: 31648322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Pattern and Outcomes in Newly Diagnosed Multiple Myeloma Patients Who Did Not Receive Autologous Stem Cell Transplantation: A Real-World Observational Study : Treatment pattern and outcomes in patients with multiple myeloma.
    He J; Schmerold L; Van Rampelbergh R; Qiu L; Potluri R; Dasgupta A; Li L; Li Y; Hu P; Nemat S; Smugar SS; Zeltzer P; Appiani C; Li Q; Mehra M; Richarz U
    Adv Ther; 2021 Jan; 38(1):640-659. PubMed ID: 33211297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
    Olszewski AJ; Barth PM; Reagan JL
    Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
    Mian H; Fiala M; Wildes TM
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):98-104.e1. PubMed ID: 31843543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disparities in utilization of autologous hematopoietic cell transplantation for treatment of multiple myeloma.
    Costa LJ; Huang JX; Hari PN
    Biol Blood Marrow Transplant; 2015 Apr; 21(4):701-6. PubMed ID: 25555447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissecting racial disparities in multiple myeloma.
    Marinac CR; Ghobrial IM; Birmann BM; Soiffer J; Rebbeck TR
    Blood Cancer J; 2020 Feb; 10(2):19. PubMed ID: 32066732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African American Patients With Multiple Myeloma: Optimizing Care to Decrease Racial Disparities.
    Pierre A; Williams TH
    Clin J Oncol Nurs; 2020 Aug; 24(4):439-443. PubMed ID: 32678364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.
    Fiala MA; Finney JD; Stockerl-Goldstein KE; Tomasson MH; DiPersio JF; Vij R; Wildes TM
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1153-4. PubMed ID: 25771403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.